SLC25A36: A Potential Drug Target Or Biomarker (G55186)

Target Name: SLC25A36

NCBI ID: G55186

SLC25A36

SLC25A36: A Potential Drug Target Or Biomarker

SLC25A36 (DKFZp564C053) is a protein that is expressed in various tissues throughout the body. It is a member of the sulfate transport family 25 (SLC25) and is involved in the transport of sulfate ions across cell membranes. SLC25A36 has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SLC25A36 is a 21-kDa protein that is expressed in a variety of tissues, including the brain, heart, liver, and pancreas. It is primarily localized to the endoplasmic reticulum (ER) and is involved in the transport of sulfate ions across the cell membrane. SLC25A36 is composed of two distinct subunits, A and B, that are held together by a disulfide bond.

SLC25A36 has been shown to play a role in several physiological processes in the body, including the regulation of ion homeostasis, cell signaling, and neurotransmitter transport. SLC25A36 is also involved in the transport of various sulfate ions, including cysteine, which is a key component of proteins and is involved in many cellular processes.

SLC25A36 has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that inhibiting SLC25A36 can inhibit the growth of cancer cells and reduce neurodegeneration in neurodegenerative diseases. Additionally, SLC25A36 has been shown to be involved in the development of autoimmune disorders, and inhibiting its activity has been shown to be effective in treating autoimmune disorders.

In addition to its potential as a drug target or biomarker, SLC25A36 is also a promising research tool for studying the underlying mechanisms of several diseases. For example, studies have shown that SLC25A36 is involved in the regulation of cell signaling and that it can interact with other proteins to regulate cellular processes. Additionally, SLC25A36 has been shown to play a role in the regulation of ion homeostasis, and studying its role in this process could provide insights into the mechanisms of many diseases.

Overall, SLC25A36 is a protein that has been identified as a potential drug target or biomarker for several diseases. Its role in the regulation of ion homeostasis, cell signaling, and neurotransmission makes it an attractive target for the development of new treatments for a variety of conditions. Further research is needed to fully understand the role of SLC25A36 in disease and to develop effective treatments.

Protein Name: Solute Carrier Family 25 Member 36

Functions: Mitochondrial transporter that imports/exports pyrimidine nucleotides into and from mitochondria. Selectively transports cytosine, guanosine, inosine and uridine (deoxy)nucleoside mono-, di-, and triphosphates by antiport mechanism. Catalyzes uniport at much lower rate (PubMed:25320081). May import (deoxy)nucleoside triphosphates in exchange for intramitochondrial (deoxy)nucleoside mono- and diphosphates, thus providing precursors necessary for de novo synthesis of mitochondrial DNA and RNA while exporting products of their catabolism (PubMed:25320081). Participates in mitochondrial genome maintenance, regulation of mitochondrial membrane potential and mitochondrial respiration

The "SLC25A36 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A36 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets